Drug intelligence / Profile preview

LN435a

Development stage: Preclinical
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

LN435a is a small molecule inhibitor of transforming growth factor beta receptor 1 (TGFBR1) developed by the Guangdong Provincial Hospital of Chinese Medicine. Derived from structural modifications of the natural alkaloid harmine, LN435a targets TGFBR1 to block the TGF-beta signaling pathway. It has demonstrated promising anti-tumor and anti-metastatic activity in breast cancer models, including patient-derived organoids (PDOs) and patient-derived tumor xenografts (PDX). By inhibiting TGFBR1, LN435a suppresses epithelial-mesenchymal transition (EMT) and cancer stem cell markers, reducing breast cancer extravasation and lung metastasis.

Targets

TGFBR1

Beyond the preview

Go deeper on LN435a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LN435a.

Explore the full profile